-
Ondexxya quickly reverses the anticoagulant effect of Apixaban or Rivaroxaban!
Time of Update: 2021-04-17
UK NHS cost regulators have provided financial support for the Alexion's Ondexxya (andexanet alfa), to reverse the direct factor Xa (FXa) inhibitor apixaban ( apixaban ) or rivaroxaban (rivaroxaban) anticoagulation, Argentina Pixaban or rivaroxaban may cause fatal or uncontrolled bleeding from the gastrointestinal (GI) of the patient.
-
Primary doctor learning platform
Time of Update: 2021-04-17
) Receive 20 yuan per person as a call fee reward, and invite the first iPhone 12 with the highest effective user, a translation pen for the second one, and 500 yuan for the third call (one copy.
-
Blood: Efficacy and safety of Ivosidenib or Enasidenib combined with intensive chemotherapy for newly diagnosed AML adult patients
Time of Update: 2021-04-17
In patients receiving Ivosidenib+ intensive chemotherapy, the frequency and grade of QT interval prolongation are similar to those observed during Ivosidenib monotherapyBasic mutation profile and best overall clinical responseBasic mutation profile and best overall clinical responseIn patients receiving Ivosidenib (n=60) or Enasidenib (n=91), the complete remission rate after induction was 55% and 47%, respectively, with CR/CR with incomplete neutrophil or platelet recovery (CR/CRi/ CRp) rates were 72% and 63%, respectively .
-
JCO: Brentuximab Vedotin can significantly reduce the dose of radiotherapy in children with high-risk HL without affecting the efficacy
Time of Update: 2021-04-17
A patient who received radiotherapy experienced disease progression at the end of the treatment and remained disease-free for more than 6 years after the rescue treatmentIn summary, the combination of Bentuximab and Vidotin as the first-line treatment of children with high-risk HL has high tolerance, can significantly reduce radiation exposure, and can obtain good curative effects .
-
Blood: Efficacy of Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in children
Time of Update: 2021-04-17
Inotuzumab ozogamicin (InO) is a new type of CD22 targeting antibody-drug conjugate FDAThis study is a phase 1 trial to study the efficacy and safety of the recommended phase 2 dose of InO (RP2D) in children with multiple relapse/refractory (R/R) CD22+ ALL .
-
JCO: The impact of ultra-high resolution matching on the prognosis of unrelated donor hematopoietic cell transplantation
Time of Update: 2021-04-17
Recently, a new article " Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation " published in " J Clin Oncol " reported the results of a large multi-center validation study.
-
Leukemia: T cell gene mutation analysis in patients with immune-mediated acquired aplastic anemia
Time of Update: 2021-04-17
All in all, the results of the study revealed that somatic mutations in T cells are more common and are related to the clonality of cells, and can change the phenotype of T cells.
-
JACC: Correlation between clonal hematopoiesis and the risk of heart failure progression with reduced left ventricular ejection fraction
Time of Update: 2021-04-17
. stem cellIn population-based studies and patients with ischemic heart failure (HF) and reduced left ventricular ejection fraction (LVEF), clonal hematopoiesis driven by somatic mutations in hematopoietic cells is often referred to as uncertain potential clonal hematopoiesis (CHIP), and medsci.
-
JCO: The effect of oral azacitidine on patients with low-risk myelodysplastic syndromes
Time of Update: 2021-04-14
Recently, the Journal of Clinical Oncology published a study online that showed that although CC-486 can increase the proportion of patients with LR-MDS that do not rely on red blood cell transfusion,
-
FDA update | Approved targeted BCMA CAR-T cell therapy idecabtagene vicleucel to treat patients with multiple myeloma
Time of Update: 2021-04-14
S. Food and Drug Administration (FDA) approved idecabtagene vicleucel for the treatment of relapsed/refractory multiple cases that have previously received ≥4-line therapies (including immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies) Adult patients with sexual myeloma.
-
Nat Commun: lncRNA HOXBLINC promotes the occurrence of acute myeloid leukemia with NPM1 mutation
Time of Update: 2021-04-14
In this study, the researchers found that the activation of long non-coding RNA (lncRNA) HOXBLINC is a key downstream mediator of the NPM1c+-related leukemia transcription program and the occurrence of leukemia.
-
Eur Respir J: The relationship between blood eosinophil count and obstructive pulmonary disease
Time of Update: 2021-04-14
03823-2020" target="_blank" rel="noopener">Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study .
03823-2020" target="_blank" rel="noopener">Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study in this message
-
Nature medicine: Pay attention to COVID-19 post-acute syndrome
Time of Update: 2021-04-14
The article defines post-acute viral syndrome as the onset of SARS-CoV-2 infection with persistent symptoms and / or delayed or long-term complications more than 4 weeks.
-
Japan's Ministry of Health, Labour and Welfare approves CAR-T cell therapy Breyanzi for the treatment of DLBCL and follicular lymphoma
Time of Update: 2021-04-13
LymphomaBristol-Myers Squibb recently announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan has approved Breyanzi (lisocabtagene maraleucel, liso-cel), a chimeric antigen receptor (CAR) T cell therapy targeting CD19 for the treatment of relapse Or refractory patients (R/R) large B-cell lymphoma and R/R follicular lymphoma.
-
BMS' CAR-T cell therapy for multiple myeloma has been approved by the FDA
Time of Update: 2021-04-13
Bristol Myers Squibb (BMS) and Bluebird Bio announced on Friday that the FDA has approved its application for BCMA - targeted CAR-T cell therapy Abecma (idecabtagene vicleucel) to treat relapsed or refractory multiple bone marrow Tumor patients.
-
This malignant hematological disease has a higher incidence rate than leukemia, but few people know about it
Time of Update: 2021-04-13
After consultation with Li Qingshan, the director of the Department of Hematology of the Honghui Hospital, combined with the results of blood routines-white blood cell elevation with anemia, thrombocytopenia, red blood cells arranged in a money-like arrangement, it is considered that Grandma Li may have suffered from plasma cell disease.
-
Eur J Heart Fail: The effect of dapagliflozin on anemia in heart failure patients with reduced ejection fraction
Time of Update: 2021-04-13
analyzed the effect of dapagliflozin on correcting anemia in HF patients with reduced ejection fraction in the DAPA-HF trial, and analyzed the effect of dapagliflozin on the prognosis of patients based on the anemia status at baseline.
-
Nature Communications: Remdesivir combination therapy can treat advanced Marburg virus disease
Time of Update: 2021-04-13
A new study conducted by Galveston National Laboratory (UTMB) at the University of Texas at Galveston shows that the combination of monoclonal antibodies and the antiviral drug Remdesivir has great benefits in the treatment of advanced Marburg virus infections .
-
Nature Metabolism: Subverting cognition: The culprit of dizziness and mobility impairment after drinking is not alcohol, but its metabolite acetic acid
Time of Update: 2021-04-13
On March 22, 2021, the team of Professor Zhang Li from the National Institutes of Health (NIH) Institute of Alcohol Abuse and Alcoholism (NIAAA) published in the journal Nature Metabolism the title: Brain ethanol metabolism by astrocytic ALDH2 drives the behavioural effects of The research paper of ethanol intoxication, which was also selected as the cover paper of the current issue.
-
Cancer: The risk and related factors of post-traumatic stress disorder in patients with acute myeloid leukemia during intensive chemotherapy
Time of Update: 2021-04-13
Acute myeloid leukemia (AML) patients undergoing intensive chemotherapy not only face life-threatening diseases, require isolation and hospitalization, but also have many physical and psychological symptoms .
